OS Therapies Inc. - Q1 2025 10-Q Summary
Business Context and Reporting Period
OS Therapies Inc. (OSTX) is a clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma and other solid tumors. The reporting period covers the three months ended March 31, 2025. The company operates as a single segment and is classified as a smaller reporting company and an emerging growth company. As of March 31, 2025, the company had one ongoing clinical trial for its lead product candidate, OST-HER2.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,876,859) | $(1,458,992) |
| Loss per Share (Basic & Diluted) | $(0.18) | $(0.25) |
| Operating Expenses | $4,999,486 | $630,232 |
| Cash and Cash Equivalents (End of Period) | $2,971,007 | $100,231 |
| Net Cash Used in Operating Activities | $(3,441,884) | $(641,729) |
| Net Cash Provided by Financing Activities | $1,053,000 | $702,978 |
| Total Assets | $4,249,931 | $5,538,797 |
| Total Liabilities | $3,636,265 | $4,727,310 |
| Stockholders' Deficit | $(4,186,578) | $(3,266,538) |
Material Changes vs. Prior Period
- Expense Surge: Operating expenses increased significantly from $0.63 million in Q1 2024 to $5.0 million in Q1 2025. Research & Development (R&D) expenses rose to $1.31 million (from $0.36 million), driven by Phase IIb clinical trial preparation. General & Administrative (G&A) expenses jumped to $3.69 million (from $0.27 million), primarily due to marketing and advisory fees associated with recent PIPE financing and equity line of credit activities.
- Net Loss Increase: Net loss widened to $3.88 million from $1.46 million. However, this was partially offset by a non-cash gain of $1.12 million from the change in fair value of warrant liabilities, compared to interest expenses of $0.83 million in the prior year.
- Liquidity Position: Cash balances decreased by $2.56 million during the quarter to $2.97 million, despite $1.05 million in financing proceeds from the sale of Series A Preferred Stock and Warrants.
- Restatement: The company revised its December 31, 2024 financial statements to correct an immaterial error regarding the recording of a deemed dividend on Series A Convertible Preferred Stock ($1.97 million), which adjusted the mezzanine equity and accumulated deficit.
Guidance, Outlook, and Risks
- Clinical Progress: The company announced that its Phase IIb clinical trial for OST-HER2 achieved its primary endpoint with statistical significance. Management plans to request an FDA Type B or Type C meeting in Q2 2025 to discuss the path to a Biologics License Application (BLA).
- Capital Needs: The company has incurred net losses since inception and has negative operating cash flows, raising substantial doubt about its ability to continue as a going concern. Operations are dependent on obtaining additional capital through public or private financing.
- Recent Transactions:
- PIPE Financing: Raised approximately $7.1 million in gross proceeds via Series A Preferred Stock and Warrants in late 2024 and early 2025. Stockholder approval for the issuance of underlying common stock was obtained in April 2025.
- Acquisition: In April 2025 (subsequent event), the company acquired HER2 Assets from Ayala Pharmaceuticals for $8.0 million (cash and stock), adding two IND filings for non-small cell lung cancer and prostate cancer.
- Risks: Key risks include the need for additional funding, the uncertainty of regulatory approval, and the potential for significant future milestone payments under licensing agreements with Ayala (formerly Advaxis) and BlinkBio. The company also disclosed ineffective internal controls over financial reporting due to a lack of segregation of duties.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.97 million cash balance against the projected burn rate, given the company's statement that it can fund operations for only 9-12 months.
- Warrant Liability Volatility: Monitor the fair value of the $1.18 million warrant liability, as fluctuations in stock price and volatility assumptions will create significant non-cash gains or losses impacting net income.
- Acquisition Dilution: Review the terms of the Ayala acquisition, specifically the issuance of ~4.77 million shares (partially via warrants) and the impact on existing shareholder dilution.
- Licensing Milestones: Assess the financial impact of upcoming milestone payments, including the $5.0 million payment to Ayala upon FDA regulatory approval or initiation of a registrational trial.
- Internal Controls: Evaluate the remediation plan for the disclosed material weaknesses in internal controls regarding segregation of duties and written policies.